The city of Chicago, Illinois, currently has 41 active clinical trials seeking participants for Diabetes research studies.
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: University of Chicago Medicine, Chicago, Illinois
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Recruiting
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of s... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/28/2025
Locations: Northwestern University Feinberg School of Medicine, Chicago, Illinois
Conditions: Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Recruiting
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
05/25/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Type 2 Diabetes
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
Recruiting
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/22/2025
Locations: Northwestern Organ Transplant Center, Chicago, Illinois +1 locations
Conditions: Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
Diabetes Toolkit at Discharge
Recruiting
The purpose of this randomized clinical trial is to implement the DM Discharge Toolkit into hospital discharge and assess the effect of the DM Discharge Toolkit on patients newly requiring insulin.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/20/2025
Locations: Northwestern Memorial Hospital, Chicago, Illinois
Conditions: Diabetes Mellitus, Type 2, Insulin Dependent Diabetes
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting
Recruiting
This is an observational study in people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who will be receiving finerenone. Kidneys filter extra water and waste out of the blood and make urine. CKD is a long-term, progressive, decrease in the kidneys' ability to filter the blood properly. In people with T2D, the body does not make enough of a hormone called insulin, or does not use insulin well enough, resulting in high blood sugar levels that can cause damage to the kidneys. As a re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Cook County Health, Chicago, Illinois +2 locations
Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Mechanisms of Prediabetic States in Sleep Apnea
Recruiting
The purpose of this study is to better understand how sleep apnea contributes to the development of diabetes.
Gender:
ALL
Ages:
Between 20 years and 65 years
Trial Updated:
05/19/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Sleep Apnea, Pre-diabetes
Enhancing Diabetes Care: Exposome &Amp; Sensors
Recruiting
The study aims to integrate various data types, such as electronic health records, wearable device data, and environmental data, to create a comprehensive, personalized diabetes care model. The study will focus on people with type 2 diabetes living in specified vulnerable zip codes.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/16/2025
Locations: University of Illinois - Chicago, Chicago, Illinois +1 locations
Conditions: Type 2 Diabetes
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
Recruiting
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/12/2025
Locations: Research Site, Chicago, Illinois
Conditions: Endocrinology, Diabetes, Type II, Obesity
MegaNatural BP® GSE on Blood Pressure and Cardiometabolic Risk Factors
Recruiting
Inflammation and stressors can interfere with the function of the lining of blood vessels and insulin activity, therefore, investigators are aiming to see how the Grape seed Extract (GSE) called MegaNatural BP can help with limiting the effects of these factors. This research will study the effects of taking 150mg of MegaNatural BP GSE per day on blood pressure levels along with influences on heart health through assessing the function of the blood vessel lining and levels of inflammation.
Gender:
ALL
Ages:
Between 40 years and 60 years
Trial Updated:
05/07/2025
Locations: Clinical Nutrition Research Center, Chicago, Illinois
Conditions: Hypertension, Pre Diabetes
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
Recruiting
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/23/2025
Locations: Cedar-Crosse Research Center, Chicago, Illinois
Conditions: Type 2 Diabetes (T2D)
Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant
Recruiting
The goal of this observational study is to establish risk factors for post-transplant in adult individuals with cirrhosis without diabetes undergoing liver transplant evaluation. The question being addressed is: can laboratory work, anthropometric tests, functional tests, imaging, and advanced measurements such as wrist actigraphy, continuous glucose monitoring, or oral glucose tolerance testing predict the development of diabetes after liver transplant? Participants will be asked to periodica... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/22/2025
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Cirrhosis, Liver, Diabetes Mellitus Risk, Transplant; Failure, Liver, Transplant-Related Disorder